Search

Contact Us

US | EN

Contact Us

US | EN

Newsroom

News

September 29, 2026

The latest

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

argenx Stories

See where we started — and where we’re going — as we chart a new course together in immunology.

argenx Stories

play

Interested in Learning More?

Get argenx news and updates right to your inbox

Subscribe

Press Releases

September 29, 2026

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

September 17, 2026

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

September 1, 2026

argenx to Present at Upcoming Investor Conferences

August 27, 2026

argenx Completes Acquisition of Forte Biosciences, Inc.

Join the team

Dare to do more with a thriving career at argenx.

Find your career

argenx on LinkedIn

To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.

©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice